Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06627413
PHASE1

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Sponsor: Intra-Cellular Therapies, Inc.

View on ClinicalTrials.gov

Summary

Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.

Official title: A Phase 1b, Open-label Study to Determine the Pharmacokinetics, Safety, and Tolerability of Single, Ascending Doses of Lumateperone Long-acting Injectable Formulations Administered Intramuscularly to Patients With Schizophrenia or Schizoaffective Disorder

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

52

Start Date

2024-08-23

Completion Date

2025-11-20

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

Lumateperone Capsule

Lumateperone 42 mg capsule, oral administration

DRUG

Lumateperone LAI

Lumateperone LAI X500-E2 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-E3 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-X2 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-X5 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Locations (4)

Clinical Site 2

Los Alamitos, California, United States

Clinical Site 3

Atlanta, Georgia, United States

Clinical Site 4

Decatur, Georgia, United States

Clinical Site 1

Marlton, New Jersey, United States